New Directions in Chemotherapy-Induced Neutropenia

A clinician and payer discuss the impact of chemotherapy-induced neutropenia on patients as well as the healthcare system, and discuss the latest in prophylactic treatment, especially during the COVID-19 pandemic.

EP. 1: Facts About Chemotherapy-Induced Neutropenia

January 18th 2021

Lee Schwartzberg, MD, FACP, of the West Cancer Center, highlights variables that increase the risk for developing chemotherapy-induced neutropenia and its implications on patients.

EP. 2: Chemotherapy-Induced Neutropenia: Impact on Cancer Care

January 18th 2021

An overview of the impact of chemotherapy-induced neutropenia on the selection, dosage, and utilization of chemotherapy.

EP. 3: Monitoring for Chemotherapy-Induced Neutropenia

January 18th 2021

A clinician’s recommendations for appropriately monitoring patients with cancer for chemotherapy-induced neutropenia or other infections.

EP. 4: Considerations for Chemotherapy-Induced Neutropenia Prophylaxis

January 18th 2021

Suggestions regarding when it is appropriate to initiate chemotherapy-induced neutropenia prophylaxis in patients with cancer and goals of therapy.

EP. 5: Chemotherapy-Induced Neutropenia Prophylaxis: Standard of Care

January 18th 2021

A historical overview regarding the development and role of granulocyte colony-stimulating factors as prophylaxis for chemotherapy-induced neutropenia and recommendations for use.

EP. 6: CIN Prophylaxis: Treating With G-CSFs

January 18th 2021

Limitations and other factors to consider when utilizing granulocyte colony-stimulating factors as prophylaxis for chemotherapy-induced neutropenia.

EP. 7: Plinabulin With G-CSF Treatment for CIN Prophylaxis

January 18th 2021

Lee Schwartzberg, MD, FACP, of the West Cancer Center, highlights exciting data demonstrated by PROTECTIVE-2 study of plinabulin with pegfilgrastim as prevention of chemotherapy-induced neutropenia and implications for using the combination in the future.

EP. 8: CIN Prophylaxis: NCCN’s Reactions to COVID-19

January 18th 2021

Best practices for treating patients with cancer who are receiving chemotherapy to reduce the risk for chemotherapy-induced neutropenia during the COVID-19 pandemic, as recommended by modified NCCN guidelines.

EP. 9: Chemotherapy-Induced Neutropenia: Financial Burden

January 18th 2021

A payer remarks on the costs of chemotherapy-induced neutropenia (CIN) on the health system and shares thoughts on the utilization of newer therapies and delivery of CIN prophylaxis to appropriate patients.

EP. 10: Health Plans React to Chemotherapy-Induced Neutropenia

January 18th 2021

To address the impact of chemotherapy-induced neutropenia on the delivery of chemotherapy to patients, Dr John Fox discusses how health plans are best supporting members.